Alternative pathways for production of β-amyloid peptides of Alzheimer's disease

Biological Chemistry

Volumn 389, Issue 8, 2008, Pages 993-1006

  Hook, Vivian ^a,b   Schechter, Israel ^c   Demuth, Hans Ulrich ^d   Hook, Gregory ^e  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^d PROBIODRUG AG   (Germany)

^e American Life Science Pharmaceuticals Inc   (United States)

Author keywords

amyloid; secretase; Alzheimer's disease; Cathepsins; Glutaminyl cyclase; Inhibitors

Indexed keywords

5 OXOPROLINASE; ACETYLLEUCYLVALYLLYSYLLYSINAL; ALOXISTATIN; ALOXISTATIN ACID; AMYLOID; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE; BETA SECRETASE 1; CATHEPSIN B; CATHEPSIN B INHIBITOR; CATHEPSIN D; ENZYME INHIBITOR; GAMMA SECRETASE; GLUTAMIC ACID; GLUTAMINE DERIVATIVE; GLUTAMINYL CYCLASE INHIBITOR; ISOASPARTIC ACID; N (3 PROPYLCARBAMOYLOXIRANE 2 CARBONYL)ISOLEUCYLPROLINE; PYROGLUTAMATE AMYLOID BETA PROTEIN (3-40); PYROGLUTAMATE AMYLOID BETA PROTEIN (3-42); PYROGLUTAMIC ACID; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; CARBOXY TERMINAL SEQUENCE; CONFERENCE PAPER; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME KINETICS; ENZYME LOCALIZATION; ENZYME MODIFICATION; ENZYME SPECIFICITY; ENZYME SUBSTRATE; ENZYME SUBSTRATE COMPLEX; HUMAN; MEMORY CONSOLIDATION; NEUROTOXICITY; NONHUMAN; PEPTIDE SYNTHESIS; PHENOTYPIC VARIATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROCESSING; SENILE PLAQUE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ENZYME INHIBITORS; HUMANS; PEPTIDE FRAGMENTS; SUBSTRATE SPECIFICITY;

ANIMALIA;

EID: 50849088334     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/BC.2008.124     Document Type: Conference Paper

References (98)

1. Beck, M., Muller, D., and Bigl, V. (1997). Amyloid precursor protein in guinea pigs-complete cDNA sequence and alternative splicing. Biochim. Biophys. Acta 1351, 17-21.
2. Beck, M., Bigl, V., and Rossner, S. (2003). Guinea pigs as a non-transgenic model for APP processing in vitro and in vivo. Neurochem. Res. 28, 637-644.
3. Benjannet, S., Savaria, D., Laslop, A., Munzer, J.S., Chretien, M., Marcinkiewicz, M., and Seidah, N.G. (1997). α1-Antitrypsin Portland inhibits processing of precursors mediated by pro-protein convertases primarily within the constitutive secretory pathway. J. Biol. Chem. 272, 26210-26218.
4. Berg, J.M., Tymoczko, J.L., and Stryer, L. (2002). Biochemistry (New York, USA: W.H. Freeman & Co.), pp. 203-204.
5. Blennow, K., de Leon, M.J., and Zetterberg, H. (2006). Alzheimer's disease. Lancet 368, 387-403.
6. Cai, H., Wang, Y., McCarthy, D., Wen, H., Borchelt, D.R., Price, D.L., and Wong, P.C. (2001). BACE1 is the major β-secretase for generation of Aβ peptides by neurons. Nat. Neurosci. 4, 233-234.
7. Cataldo, A.M., Barnett, J.L., Berman, S.A., Li, J., Quarless, S., Bursztajn, S., Lippa, C., and Nixon, R.A. (1995). Gene expression and cellular content of cathepsin D in Alzheimer's disease brain: evidence for early up-regulation of the endosomal-lysosomal system. Neuron 14, 671-680.
8. Cirrito, J.R., Yamada, K.A., Finn, M.B., Sloviter, R.S., Bales, K.R., May, P.C., Schoepp, D.D., Paul, S.M., Mennerick, S., and Holtzman, D.M. (2005). Synaptic activity regulates interstitial fluid amyloid-β levels in vivo. Neuron 48, 913-922.
9. Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A.Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., and Selkoe, D.J. (1992). Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production. Nature 360, 672-674.
10. Clarke, S. (2003). Aging as war between chemical and biochemical processes: protein methylation and the recognition of age-damaged proteins for repair. Ageing Res. Rev. 2, 263-285.
11. Cynis, H., Schilling, S., Bodnar, M., Hoffmann, T., Heiser, U., Saido, T.C., and Demuth, H.-U. (2006). Inhibition of glutaminyl cyclase alters pyroglutamate formation in mammalian cells. Biochim. Biophys. Acta Proteins Proteomics 1764, 1618-1625.
12. Cynis, H., Schilling, S., and Demuth, H.-U. (2007). Generation of N-terminally truncated Aβ species in HEK293 cells. Neurodegen. Dis. 4 (Suppl. 1), 217.
13. Cynis, H., Scheel, E., Saido, T.C., Schilling, S., and Demuth, H.-U. (2008). Amyloidogenic processing of APP: evidence for a pivotal role of glutaminyl cyclase for generation of pyroglutamate-modified amyloid-β. Biochemistry, in press.
14. Demuth, H.-U., Böhme, L., Cynis, H., Schilling, S., and Hoffmann, T. (2007). Pathways leading to the neurotoxic pyroglutamated Aβ-peptides differ in wild type APP- and mutant APP-expressing systems. Neurodegen. Dis. 4 (Suppl. 1), 193.
15. Dewachter, I., van Dorpe, J., Spittaels, K., Tesseur, I., Van Den Haute, C., Moechars, D., and Van Leuven, F. (2000). Modeling Alzheimer's disease in transgenic mice: effect of age and of presenilin1 on amyloid biochemistry and pathology in APP/London mice. Exp. Gerontol. 35, 831-841.
16. Docherty, K. and Steiner, D.F. (1982). Post-translational proteolysis in polypeptide hormone biosynthesis. Annu. Rev. Physiol. 44, 625-638.
17. Dodart, J.C., Mathis, C., Bales, K.R., and Paul, S.M. (2002). Does my mouse have Alzheimer's disease? Genes Brain Behav. 1, 142-155.
18. Dunn, B.M., and Hung, S. (2000). The two sides of enzyme-substrate specificity: lessons from the aspartic proteinases. Biochim. Biophys. Acta 1477, 231-240.
19. Efthimiopoulos, S., Vassilacopoulou, D., Ripellino, J.A., Tezapsidis, N., and Robakis, N.K. (1996). Cholinergic agonists stimulate secretion of soluble full-length amyloid precursor protein in neuroendocrine cells. Proc. Natl. Acad. Sci. USA 93, 8046-8050.
20. Farber, S.A., Nitsch, R.M., Schulz, J.G., and Wurtman, R.J. (1995). Regulated secretion of β-amyloid precursor protein in rat brain. J. Neurosci. 15, 7442-7451.
21. Findeis, M.A. (2007). The role of amyloid β peptide 42 in Alzheimer's disease. Pharmacol. Therapeut. 116, 266-286.
22. Fugere, M., and Day, R. (2005). Cutting back on pro-protein convertases: the latest approaches to pharmacological inhibition. Trends Pharmacol. Sci. 26, 294-301.
23. Gainer, H., Russell, J.T., and Loh, Y.P. (1985). The enzymology and intracellular organization of peptide precursor processing: the secretory vesicle hypothesis. Neuroendocrinology 40, 171-184.
24. Galletti, P., Ingrosso, D., Manna, C., Clemente, G., and Zappia, V. (1995). Protein damage and methylation-mediated repair in the erythrocyte. Biochem. J. 306, 313-325.
25. Gandy, S., Martins, R.N., and Buxbaum, J. (2003). Molecular and cellular basis for anti-amyloid therapy in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 17, 259-266.
26. Gensberg, K., Jan, S., and Matthews, G.M. (1998). Subtilisin-related serine proteases in the mammalian constitutive secretory pathway. Semin. Cell Dev. Biol. 9, 11-17.
27. Gumbiner, B. and Kelly, R.B. (1982). Two distinct intracellular pathways transport secretory and membrane glycoproteins to the surface of pituitary tumor cells. Cell 28, 51-59.
28. Halfon, S., Baird, T.T., and Craik, C.S. (2004). Trypsin. In: Handbook of Proteolytic Enzymes, A.J. Barrett, N.D. Rawlings and J.F. Woesnner, eds. (San Diego, USA: Elsevier Academic Press), pp. 1483-1488.
29. Haass, C. and Selkoe, D.F. (2007). Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide. Nat. Rev. Mol. Cell Biol. 8, 101-112.
30. He, W. and Barrow, C.J. (1999). The Aβ3-pyroglutamyl and 11-pyroglutamyl peptides found in senile plaque have greater β-sheet forming and aggregation propensities in vitro than full-length Aβ. Biochemistry 38, 10871-10877.
31. Hirata-Fukae, C., Sidahmed, E.HY., Gooskens, T.P., Aisen, P.S., Dewachter, I., Devijver, H., Van Leuven, F.V., and Matsuoka, Y. (2008). β-site amyloid precursor protein-cleaving enzyme-1 (BACE1)-mediated changes of endogenous amyloid beta in wild-type and transgenic mice in vivo. Neursosci. Lett. 435, 186-189.
32. Hook, V.Y.H., Toneff, T., Aaron, W., Yasothornsrikul, S., Bundey, R., and Reisine, T. (2002). β-Amyloid peptide in regulated secretory vesicles of chromaffin cells: evidence for multiple cysteine proteolytic activities in distinct pathways for β-secretase activity in chromaffin vesicles. J. Neurochem. 81, 237-256.
33. Hook, V., Yasothornsrikul, S., Greenbaum, D., Medzihradszky, K.F., Troutner, K., Toneff, T., Bundey, R., Logrinova, A., Reinheckel, T., Peters, C., and Bogyo, M. (2004). Cathepsin L and Arg/Lys aminopeptidase: a distinct prohormone processing pathway for the biosynthesis of peptide neurotransmitters and hormones. Biol. Chem. 385, 473-480.
34. Hook, V., Toneff, T., Bogyo, M., Medzihradszky, K.F., Nevenu, J., Lane, W., Hook, G., and Reisine, T. (2005). Inhibition of cathepsin B reduces β-amyloid production in regulated secretory vesicles of neuronal chromaffin cells: evidence for cathepsin B as a candidate β-secretase of Alzheimer's disease. Biol. Chem. 386, 931-940.
35. Hook, G., Hook, V.Y., and Kindy, M. (2007a). Cysteine protease inhibitors reduce brain β-amyloid and β-secretase activity in vivo and are potential Alzheimer's disease therapeutics. Biol. Chem. 388, 979-983.
36. Hook, V., Kindy, M., and Hook, G. (2007b). Cysteine protease inhibitors effectively reduce in vivo levels of brain β-amyloid related to Alzheimer's disease. Biol. Chem. 388, 247-252.
37. Hook, V.Y., Kindy, M., and Hook, G. (2008). Inhibitors of cathepsin B improve memory and reduce Aβ in transgenic Alzheimer's disease mice expressing the wild-type, but not the Swedish mutant, β-secretase APP site. J. Biol. Chem. 283, 7745-7753.
38. Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., and Cole, G. (1996). Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science 274, 99-102.
39. Iversen, L.L., Mortishire-Smith, R.J., Pollack, S.J., and Shearman, M.S. (1995). The toxicity in vitro of β-amyloid protein. Biochem. J. 311, 1-16.
40. Jacks, T. (1996). Tumor suppressor gene mutations in mice. Annu. Rev. Genet. 30, 603-636.
41. Johnstone, E.M., Chaney, M.O., Norris, F.H., Pascual, R., and Little, S.P. (1991). Conservation of the sequence of the Alzheimer's disease amyloid peptide in dog, polar bear and five other mammals by cross-species polymerase chain reaction analysis. Brain Res. Mol. Brain Res. 10, 299-305.
42. Jolly-Tornetta, C., Gao, Z.Y., Lee, V.M., and Wolf, B.A. (1998). Regulation of amyloid precursor protein secretion by glutamate receptors in human Ntera 2 neurons. J. Biol. Chem. 273, 14015-14021.
43. Kim, J., Onstead, L., Randle, S., Price, R., Smithson, L., Zwizinski, C., Dickson, D.W., Golde, T., and McGowan, E. (2007). Aβ40 inhibits amyloid deposition in vivo. J. Neurosci. 17, 627-633.
44. Kuo, Y.M., Emmerling, M.R., Woods, A.S., Cotter, R.J., and Roher, A.E. (1997). Isolation, chemical characterization, and quantitation of Aβ 3-pyroglutamyl peptide from neuritic plaques and vascular amyloid deposits. Biochem. Biophys. Res. Commun. 237, 188-191.
45. Ladror, U.S., Snyder, S.W., Wang, G.T., Holzman, T.F., and Krafft, G.A. (1994). Cleavage at the amino and carboxyl termini of Alzheimer's amyloid-β by cathepsin D. J. Biol. Chem. 269, 18422-18428.
46. Lin, X., Koelsch, G., Wu, S., Downs, D., Dashti, A., and Tang, J. (2000). Human aspartic protease memapsin 2 cleaves the bsecretase site of beta-amyloid precursor protein. Proc. Natl. Acad. Sci. USA 97, 1456-1460.
47. Lodish, H., Berk, A., Zipursky, S.L., Matsudaira, P., Baltimore, D., and Danell, J. (1999). Molecular Cell Biology (New York, USA: W.H. Freeman), pp. 691-726.
48. Luo, Y., Bolon, B., Kahn, S., Bennett, B.D., Babu-Khan, S., Denis, P., Fan, W., Kha, H., Zhang, J., Gong, Y., et al. (2001). Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation. Nat. Neurosci. 4, 231-232.
49. Masliah, E. and Rockenstein, E. (2000). Genetically altered transgenic models of Alzheimer's disease. J. Neural Transm. Suppl. 59, 175-183.
50. Maeda, J., Ji, B., Irie, T., Tomiyama, T., Maruyama, M., Okauchi, T., Staufenbiel, M., Iwata, N., Ono, M., Saido, T., et al. (2007). Longitudinal, quantitative assessment of amyloid, neuro-inflammation, and anti-amyloid treatment in a living mouse model of Alzheimer's disease enabled by positron emission tomography. J. Neurosci. 27, 10957-10968.
51. McConnell, R.M., York, J.L., Frizzell, D., and Ezell, C. (1993). Inhibition studies of some serine and thiol proteinases by new leupeptin analogues. J. Med. Chem. 36, 1084-1089.
52. McGowan, E., Pickford, F., Kim, J., Onstead, L., Eriksen, J., Yu, C., Skipper, L., Murphy, M.P., Beard, J., Das, P., et al. (2005). Aβ42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron 47, 191-199.
53. Moechars, D., Dewachter, I., Lorent, K., Reverse, D., Baekelandt, V., Naidu, A., Tesseur, I., Spittaels, K., Haute, C.V., Checler, F., et al. (1999). Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain. J. Biol. Chem. 274, 6483-6492.
54. Mort, J.S. (2004). Cathepsin B. In: Handbook of Proteolytic Enzymes, A.J. Barrett, N.D. Rawlings and J.F. Woesnner, eds. (San Diego, CA: Elsevier Academic Press), pp. 1079-1086.
55. Moss, M.L., Jin, S.L., Milla, M.E., Bickett, D.M., Burkhart, W., Carter, H.L., Chen, W.J., Clay, W.C., Didsbury, J.R., Hassler, D., et al. (1997). Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-α. Nature 385, 733-736.
56. Nicholson, D.W. and Thornberry, N.A. (1997). Caspases: killer proteases. Trends Biochem. Sci. 22, 299-306.
57. Nitsch, R.M., Slack, B.E., Wurtman, R.J., and Growdon, J.H. (1992). Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 258, 304-307.
58. Nitsch, R.M., Farber, S.A., Growdon, J.H., and Wurtman, R.J. (1993). Release of amyloid β-protein precursor derivatives by electrical depolarization of rat hippocampal slices. Proc. Natl. Acad. Sci. USA 90, 5191-5193.
59. Piccini, A., Russo, C., Gliozzi, A., Relini, A., Vitali, A., Borghi, R., Giliberto, L., Armirotti, A., D'Arrigo, C., Bachi, A., et al. (2005). β-Amyloid is different in normal aging and in Alzheimer disease. J. Biol. Chem. 280, 34186-34192.
60. Price, D.L. and Sisodia, S.S. (1998). Mutant genes in familial Alzheimer's disease and transgenic models. Annu. Rev. Neurosci. 21, 479-505.
61. Rawlings, N.D. and Barrett, A.J. (2004) Introduction: the clans and families of cysteine proteases. In: Handbook of Proteolytic Enzymes, A.J. Barrett, N.D. Rawlings and J.F. Woesnner, eds. (San Diego, CA: Elsevier Academic Press), pp. 1051-1057.
62. Roberds, S.L., Anderson, J., Basi, G., Bienkowski, M.J., Branstetter, D.G., Chen, K.S., Freedman, S.B., Frigon, N.L., Games, D., Hu, K., et al. (2001). BACE knockout mice are healthy despite lacking the primary β-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum. Mol. Genet. 10, 1317-1324.
63. Roher, A.E., Lowenson, J.D., Clarke, S., Wolkow, C., Wang, R., Cotter, R.J., Reardon, I.M., Ziircher-Neely, H.A., Heinrikson, R.L., Ball, M.J., et al. (1993). Structural alterations in the peptide backbone of β-amyloid core protein may account for its deposition and stability in Alzheimer's disease. J. Biol. Chem. 286, 3072-3083.
64. Russo, C., Violani, E., Salis, S., Venezia, V., Dolcini, V., Damonte, G., Benatti, U., D'Arrigo, C., Patrone, E., Carlo, P., et al. (2002) Pyroglutamate-modified amyloid β-peptides-AβN3(pE)-strongly affect cultured neuron and astrocyte survival. J. Neurochem. 82, 1480-1489.
65. Saftig, P., Peters, C., von Figura, K., Craessaerts, K., Van Leuven, F., and De Strooper, B. (1996). Amyloidogenic processing of human amyloid precursor protein in hippocampal neurons devoid of cathepsin D. J. Biol. Chem. 271, 27241-27244.
66. Saido, T.C. (1998). Alzheimer's disease as proteolytic disorders: anabolism and catabolism of β-amyloid. Neurobiol. Aging 19, 69-75.
67. Saido, T.C., Iwatsubo, T., Mann, D.M., Shimada, H., Ihara, Y., and Kawashima, S. (1995). Dominant and differential deposition of distinct β-amyloid peptide species, Aβ N3(pE), in senile plaques. Neuron 14, 457-466.
68. Saido, T.C., Yamao-Harigaya, W., Iwatsubo, T., and Kawashima, zS. (1996). Amino- and carboxyl-terminal heterogeneity of β-amyloid peptides deposited in human brain. Neurosci. Lett. 215, 173-176.
69. Schechter, I. (1970). On the active sites of proteases. Cleavage of peptide bonds involving D-alanine residues by carboxypeptidase A. Eur. J. Biochem. 14, 516-520.
70. Schechter, I. (2005). Mapping of the active site of proteases in the 1960s and rational design of inhibitors/drugs in the 1990s. Curr. Protein Pept. Sci. 6, 501-512.
71. Schechter, I. and Berger, A. (1967). On the size of the active site in proteases. I. Papain. Biochem. Biophys. Res. Commun. 27, 157-162.
72. Schechter, I. and Berger, A. (1968). On the active site of proteases III. Mapping the active site of papain; specific peptide inhibitors of papain. Biochem. Biophys. Res. Commun. 32, 898-902.
73. Schechter, I. and Ziv, E. (2008). Kinetic properties of cathepsin D and BACE 1 indicate the need to search for additional β-secretase candidate(s). Biol. Chem. 389, 313-320.
74. Schilling, S., Hoffmann, T., Manhart, S., Hoffmann, M., and Demuth, H.-U. (2004). Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions. FEBS Lett. 563, 191-196.
75. Schilling, S., Lauber, T., Schaupp, M., Manhart, S., Scheel, E., Bohm, G., and Demuth, H.U. (2006). On the seeding and oligomerization of pGlu-amyloid peptides (in vitro). Biochemistry 45, 12393-12399.
76. Schilling, S., Cynis, H., and Demuth, H.-U. (2007). Pyroglutamated Aβ peptides: N-terminally modified Aβ variants generated by glutam(in)yl cyclase. Neurodegen. Dis. 4 (Suppl. 1), 192-193.
77. Schilling, S., Wasternack, C., and Demuth, H.-U. (2008). Glutaminyl cyclases from animals and plants: a case of functionally convergent protein evolution. Biol. Chem. 389, 983-991.
78. Seidah, N.G., Chretien, M., and Day, R. (1994). The family of subtilisin/kexin like pro-protein and pro-hormone convertases: divergent or shared functions. Biochimie 76, 197-209.
79. Selkoe, D.J. (2001). Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81, 741-766.
80. Selkoe, D.F. (2004). Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases. Nat. Cell Biol. 6, 1054-1061.
81. Selkoe, D.F. and Wolfe, M. (2007). Presenilin: running with scissors in the membrane. Cell 131, 215-221.
82. Shi, X.P., Chen, E., Yin, K.C., Na, S., Garsky, V.M., Lai, M.T., Li, Y.M., Platchek, M., Register, R.B., Sardana, M.K., et al. (2001). The pro domain of β-secretase does not confer strict zymogen-like properties but does assist proper folding of the protease domain. J. Biol. Chem. 276, 10366-10373.
83. Shimizu, T., Watanabe, A., Ogawara, M., Mori, H., and Shirasawa, T. (2000). Isoaspartate formation and neurodegeneration in Alzheimer's disease. Arch. Biochem. Biophys. 381, 225-234.
84. Shimizu, T., Matsuoka, Y., and Shirasawa, T. (2005). Biological significance of isoaspartate and its repair system. Biol. Pharm. Bull. 28, 1590-1596.
85. Sisodia, S.S. (1999). Alzheimer's disease: perspectives for the new millennium. J. Clin. Invest. 104, 1169-1170.
86. Tamai, M., Matsumoto, K., Omura, S., Koyama, I., Ozawa, Y., and Hanada, K. (1986). In vitro and in vivo inhibition of cysteine proteinases by EST, a new analog of E-64. J. Pharmacobiodyn. 9, 672-677.
87. 2+-free calmodulin and calmodulin damaged by in vitro aging are selectively degraded by 26S proteasomes without ubiquitination. J. Biol. Chem. 275, 20295-20301.
88. Tezapsidis, N., Li, H.-G., Ripellino, J.A., Efthimiopoulos, S., Vassilacopoulou, D., Sambamurti, K., Toneff, T., Yasothornsrikul, S., Hook, V.Y.H., and Robakis, N.K. (1998). Release of non-transmembrane full-length Alzheimer's amyloid precursor protein from the lumenar surface of chromaffin granule membranes. Biochemistry 37, 1274-1282.
89. Thomas, G. (2002). Furin at the cutting edge: from protein traffic to embryogenesis and disease. Nat. Rev. Mol. Cell Biol. 3, 753-766.
90. Towatari, T., Nikawa, T., Murata, M., Yokoo, C., Tamai, M., Hanada, K., and Katunuma, N. (1991). Novel epoxysuccinyl peptides. A selective inhibitor of cathepsin B, in vivo. FEBS Lett. 280, 311-315.
91. Turner, R.S. (2006). Alzheimer's disease. Semin. Neurol. 26, 499-506.
92. Turner, R.T. III, Koelsch, G., Hong, L., Castanheira, P., Ermolieff, J., Ghosh, A.K., and Tang, J. (2001). Subsite specificity of memapsin 2 (β-secretase): implications for inhibitor design. Biochemistry 40, 10001-10006.
93. Vassar, R. (2004). BACE1: the β-secretase enzyme in Alzheimer's disease. J. Mol. Neurosci. 23, 105-114.
94. Vassar, R., Bennett, B.D., Babu-Khan, S., Kahn, S., Mendiaz, E.A., Denis, P., Teplow, D.B., Ross, S., Amarante, P., Loeloff, R., et al. (1999). β-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735-741.
95. Vigneswara, V., Lowenson, J.D., Powell, C.D., Thakur, M., Bailey, K., Clarke, S., Ray, D.E., and Carter, W.G. (2006). Proteomic identification of novel substrates of a protein isoaspartyl methyltransferase repair enzyme. J. Biol. Chem. 281, 32619-32629.
96. Voet, D. and Voet, J.G. (2004). Biochemistry (New York, USA: John Wiley & Sons), pp. 480-481.
97. Wolfe, M.S. (2006). Shutting down Alzheimer's. Sci. Am. 294, 72-79.
98. Zhou, A., Webb, G., Zhu, X., and Steiner, D.F. (1999). Proteolytic processing in the secretory pathway. J. Biol. Chem. 274, 20745-20748.